Abstract
A surfeit of errors and an absence of sufficiently rigorous neuroscience theory have led to failures of neuroscience drug developments and to less effective patient care. Alzheimer’s disease (AD) requires systematic grounding of drug developments with mechanistic explanations to replace current trial and error approaches to the development of potential drug products. We foresee the need for regulatory revisions that will provide better balanced supports for advancing the AD scientific knowledge required to more effectively develop clinically useful drugs and for provisions to patients of drug candidates soundly predicted, based on documented effects on AD neuropathologies and safety, to slow or arrest the progression of persons at-risk to AD dementia. We propose that investigators and regulators focus AD clinical research on understanding the inductions of reversible and irreversible neuropathologies and their roles in generating clinical dementia. In support of this, we foresee the need for regulatory changes to create a vehicle for these clinical studies; for example, conditional drug approvals based on drug induced neuropathological changes.
Keywords: Alzheimer clinical trials, Alzheimer’s disease, dementia trials. drug approval process, drug development, drug regulations.
Current Alzheimer Research
Title:A New Regulatory Road-Map for Alzheimer’s Disease Drug Development
Volume: 11 Issue: 3
Author(s): Robert E. Becker and Nigel H. Greig
Affiliation:
Keywords: Alzheimer clinical trials, Alzheimer’s disease, dementia trials. drug approval process, drug development, drug regulations.
Abstract: A surfeit of errors and an absence of sufficiently rigorous neuroscience theory have led to failures of neuroscience drug developments and to less effective patient care. Alzheimer’s disease (AD) requires systematic grounding of drug developments with mechanistic explanations to replace current trial and error approaches to the development of potential drug products. We foresee the need for regulatory revisions that will provide better balanced supports for advancing the AD scientific knowledge required to more effectively develop clinically useful drugs and for provisions to patients of drug candidates soundly predicted, based on documented effects on AD neuropathologies and safety, to slow or arrest the progression of persons at-risk to AD dementia. We propose that investigators and regulators focus AD clinical research on understanding the inductions of reversible and irreversible neuropathologies and their roles in generating clinical dementia. In support of this, we foresee the need for regulatory changes to create a vehicle for these clinical studies; for example, conditional drug approvals based on drug induced neuropathological changes.
Export Options
About this article
Cite this article as:
Becker E. Robert and Greig H. Nigel, A New Regulatory Road-Map for Alzheimer’s Disease Drug Development, Current Alzheimer Research 2014; 11 (3) . https://dx.doi.org/10.2174/156720501103140329210642
DOI https://dx.doi.org/10.2174/156720501103140329210642 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Current Drug Targets Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Current Alzheimer Research Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research High PIB Retention in Alzheimers Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters
Current Alzheimer Research Technological Solutions for Older People with Alzheimer’s Disease: Review
Current Alzheimer Research Fluorescence Imaging of Blood Flow Velocity in the Rodent Brain
Current Topics in Medicinal Chemistry WITHDRAWN: MicroRNA-125b can Target p38MAPK to Resolve Intermittent Hypoxia- Induced Dementia in Murine Models
Current Neurovascular Research Dietary Melatonin Protects Against Behavioural, Metabolic, Oxidative, and Organ Morphological Changes in Mice that are Fed High-Fat, High- Sugar Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Potentiality of Oxygen-Ozonetherapy to Improve the Health of Aging People
Current Aging Science Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Current Drug Discovery Technologies Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Mini-Reviews in Medicinal Chemistry Platelets in the Alzheimer’s Disease Brain: do they Play a Role in Cerebral Amyloid Angiopathy?
Current Neurovascular Research The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Long-term Potentiation at Spinal C-fiber Synapses: A Target for Pathological Pain
Current Pharmaceutical Design Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research